Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Mexico says a third of 130,000 missing people might be alive, fueling criticism from families - 2Tasting America: An Excursion Through Darling Cheap Food Brands
- 321 Things You Ought to Never Share with Your Childless Companion
- 4Discovering a true sense of harmony: Contemplation and Care Practices
- 5At least 11 killed in South Africa mass shooting
- Vote In favor of Your Favored Kind Of Attire
- ‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- The Most Astonishing Arising Advances to Watch
- Space station changes command, setting stage for Crew 11 departure
- Russia downs 16 drones heading for Moscow, mayor says
- Burkina Faso must 'forget' about democracy, military leader says
- The Tiny Channel Island With 65 Residents That Chefs And Foodies Go Out Of Their Way To Visit
- Popular Home Rug Series For You
